



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/825,984	04/16/2004	Matthew D. Soderstrom	03038-00	8747
8015 7590 01/23/2007 CYTEC INDUSTRIES INC: 1937 WEST MAIN STREET P.O. BOX 60 STAMFORD, CT 06904-0060			EXAMINER FIORITO, JAMES	
			ART UNIT 1754	PAPER NUMBER
SHORTENED STATUTORY PERIOD OF RESPONSE		MAIL DATE	DELIVERY MODE	
3 MONTHS		01/23/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary	Application No. 10/825,984	Applicant(s) SODERSTROM, MATTHEW D.	
	Examiner James A. Fiorito	Art Unit 1754	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 06 November 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-4, 7-12 and 15 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-4, 7-12, and 15 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-4, 7-12, and 15 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Virnig '055.

Virnig teaches a process for extracting and recovering copper from an aqueous solution containing copper values by contacting the aqueous solution with a water insoluble extraction reagent composition comprising aldoxime, ketoxime and a equilibrium modifier (Column 2 Line 34-45). The composition has a degree of modification of between 0.2 and 0.95, preferably between 0.4 and 0.9. Virnig teaches that the ketoxime may be 5-dodecyl-2-hydroxy acetophenone (Column 4 Lines 45-50) and that the aldoxime may be 2-hydroxy-5-nonyl benzaldoxime (Column 4 Lines 26-39) or 2-hydroxy-5-nonylbenzophenone oxime (Column 3 Lines 65-67). Virnig teaches the use of linear diester equilibrium modifiers, wherein the linear diester equilibrium modifiers perform at least equivalent to that of the equilibrium modifier 2,2,4-trimethylpentane-1,3-diol diisobutyrate (Column 7 Line 35-36). Virnig teaches linear diester equilibrium modifiers in combination with both an aldoxime alone, and aldoxime

and ketoxime together (Table 1). Virnig also teaches an aldoxime 2,2,4-trimethylpentane-1,3-diol diisobutyrate combination (Table 1).

Virnig does not expressly state that the equilibrium modifier 2,2,4-trimethylpentane-1,3-diol diisobutyrate is combined with both an aldoxime and a ketoxime. However, Virnig does combined 2,2,4-trimethylpentane-1,3-diol diisobutyrate with an aldoxime in Table 1 and in Table 1 it shows that the linear diester equilibrium modifier may be combined with an aldoxime alone (Organic Phase B) or with an aldoxime and an ketoxime (Organic Phase A). Therefore, it would be obvious to combined a 2,2,4-trimethylpentane-1,3-diol diisobutyrate an aldoxime alone as shown in Table 1 or with an aldoxime and an ketoxime even though this combination is not disclosed in Table 1. Further, there is no evidence of record of an unexpected result from the combination of an aldoxime, a ketoxime and 2,2,4-trimethylpentane-1,3-diol diisobutyrate.

Virnig teaches that the extractant is a hydroxyl aryl oxime (Claim 4) and that the hydroxyl aryl oxime may be the aldoxime 5-nonylsalicylaldoxime (Claims 6 and 10). Although, the 5-nonylsalicylaldoxime claimed by Virnig is not presented identically to the instantly claimed 2-hydroxy-5-nonylsalicylaldoxime, the 5-nonylsalicylaldoxime of Virnig is either inherently identical to 2-hydroxy-5-nonylsalicylaldoxime or it would be obvious to use 2-hydroxy-5-nonylsalicylaldoxime in the place of the 5-nonylsalicylaldoxime of Virnig. This is suggested by the fact that the 5-nonylsalicylaldoxime of Virnig is selected from **hydroxy**aryl oximes (Claims 4,6 and 10).

Response to Arguments

Applicant's arguments with respect to claim 8-12, and 15 have been considered but are moot in view of the new ground(s) of rejection.

Applicant's arguments filed 11/06/06 have been fully considered but they are not persuasive.

In response the argument that it would not have been obvious to combined the 2,2,4-trimethylpentane-1,3-diol diisobutyrate of Virnig with an aldoxime and an a ketoxime; Virnig does combined 2,2,4-trimethylpentane-1,3-diol diisobutyrate with an aldoxime in Table 1 and in Table 1 it shows that the linear diester equilibrium modifier may be combined with an aldoxime alone (Organic Phase B) or with an aldoxime and an ketoxime (Organic Phase A). Therefore, it would be obvious to combined a 2,2,4-trimethylpentane-1,3-diol diisobutyrate an aldoxime alone as shown in Table 1 or with an aldoxime and an ketoxime even though this combination is not disclosed in Table 1. Further, there is no evidence of record of an unexpected result from the combination of an aldoxime, a ketoxime and 2,2,4-trimethylpentane-1,3-diol diisobutyrate..

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP

§ 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James A. Fiorito whose telephone number is (571)272-7426. The examiner can normally be reached on 9am - 6pm.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Stanley Silverman can be reached on (571) 272-1358. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1754

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

James Fiorito
Patent Examiner
AU 1754

JF


Wayne Langel
Primary Patent Examiner
AU 1754